Do analysts recommend SONX or CTSO?

Cytosorbents has a consensus price target of $107.50, suggesting a potential upside of 3,006.94%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts clearly believe Cytosorbents is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SONX or CTSO more profitable?

Cytosorbents has a net margin of -48.94% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Sonendo -92.74% -184.01% -68.60% Cytosorbents -48.94% -431.65% -41.94%

Is TMDIF or SONX more profitable?

Titan Medical has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Titan Medical's return on equity of -82.31% beat Sonendo's return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% Sonendo -92.74% -184.01% -68.60%

Do analysts recommend IRIX or SONX?

IRIDEX currently has a consensus price target of $3.00, suggesting a potential upside of 253.65%. Given IRIDEX's stronger consensus rating and higher probable upside, research analysts plainly believe IRIDEX is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, IRIX or SONX?

IRIDEX has higher revenue and earnings than Sonendo. IRIDEX is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IRIDEX $52.67M 0.28 -$4.44M -$0.20 N/A Sonendo $44.40M 0.14 -$60.92M -$71.12 N/A

Is IRIX or SONX more profitable?

IRIDEX has a net margin of -6.88% compared to Sonendo's net margin of -92.74%. IRIDEX's return on equity of 0.00% beat Sonendo's return on equity. Company Net Margins Return on Equity Return on Assets IRIDEX -6.88% N/A -12.55% Sonendo -92.74% -184.01% -68.60%

Do analysts recommend SONX or SINT?

Sintx Technologies has a consensus price target of $9.50, indicating a potential upside of 358.94%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sintx Technologies is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is SONX or SINT more profitable?

Sonendo has a net margin of -92.74% compared to Sintx Technologies' net margin of -848.20%. Sonendo's return on equity of -184.01% beat Sintx Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Sonendo -92.74% -184.01% -68.60% Sintx Technologies -848.20% -354.44% -115.37%

Sonendo (SONX) Competitors

$1.28 0.00 (0.00%)

As of 10/12/2026

Compare

SONX vs. CTSO, TMDIF, IRIX, SINT, and NMTC

Should you buy Sonendo stock or one of its competitors? Sonendo's main competitors and comparable companies include Cytosorbents (CTSO), Titan Medical (TMDIF), IRIDEX (IRIX), Sintx Technologies (SINT), and NeuroOne Medical Technologies (NMTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Sonendo compare to Cytosorbents?

Sonendo (NYSE:SONX) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

In the previous week, Cytosorbents had 3 more articles in the media than Sonendo. MarketBeat recorded 3 mentions for Cytosorbents and 0 mentions for Sonendo. Cytosorbents' average media sentiment score of 0.61 beat Sonendo's score of 0.00 indicating that Cytosorbents is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonendo	Neutral
Cytosorbents	Positive

Sonendo has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

28.7% of Sonendo shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 7.9% of Sonendo shares are owned by insiders. Comparatively, 7.8% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cytosorbents has a consensus price target of $107.50, suggesting a potential upside of 3,006.94%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts clearly believe Cytosorbents is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cytosorbents has a net margin of -48.94% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
Cytosorbents	-48.94%	-431.65%	-41.94%

Cytosorbents has lower revenue, but higher earnings than Sonendo. Cytosorbents is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.14	-$60.92M	-$71.12	N/A
Cytosorbents	$37.06M	0.29	-$8.20M	-$5.80	N/A

Summary

Cytosorbents beats Sonendo on 11 of the 16 factors compared between the two stocks.

How does Sonendo compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Sonendo (NYSE:SONX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 28.7% of Sonendo shares are held by institutional investors. 0.0% of Titan Medical shares are held by insiders. Comparatively, 7.9% of Sonendo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Titan Medical's average media sentiment score of 0.00 equaled Sonendo'saverage media sentiment score.

Company	Overall Sentiment
Titan Medical	Neutral
Sonendo	Neutral

Titan Medical has higher earnings, but lower revenue than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.54	$6.95M	$0.05	1.66
Sonendo	$44.40M	0.14	-$60.92M	-$71.12	N/A

Titan Medical has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Titan Medical's return on equity of -82.31% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Sonendo	-92.74%	-184.01%	-68.60%

Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Sonendo has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market.

Summary

Titan Medical beats Sonendo on 6 of the 11 factors compared between the two stocks.

How does Sonendo compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and Sonendo (NYSE:SONX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

IRIDEX currently has a consensus price target of $3.00, suggesting a potential upside of 253.65%. Given IRIDEX's stronger consensus rating and higher probable upside, research analysts plainly believe IRIDEX is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

20.1% of IRIDEX shares are held by institutional investors. Comparatively, 28.7% of Sonendo shares are held by institutional investors. 8.6% of IRIDEX shares are held by company insiders. Comparatively, 7.9% of Sonendo shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, IRIDEX had 135 more articles in the media than Sonendo. MarketBeat recorded 135 mentions for IRIDEX and 0 mentions for Sonendo. IRIDEX's average media sentiment score of 0.85 beat Sonendo's score of 0.00 indicating that IRIDEX is being referred to more favorably in the media.

Company	Overall Sentiment
IRIDEX	Positive
Sonendo	Neutral

IRIDEX has higher revenue and earnings than Sonendo. IRIDEX is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.28	-$4.44M	-$0.20	N/A
Sonendo	$44.40M	0.14	-$60.92M	-$71.12	N/A

IRIDEX has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Sonendo has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market.

IRIDEX has a net margin of -6.88% compared to Sonendo's net margin of -92.74%. IRIDEX's return on equity of 0.00% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.88%	N/A	-12.55%
Sonendo	-92.74%	-184.01%	-68.60%

Summary

IRIDEX beats Sonendo on 13 of the 15 factors compared between the two stocks.

How does Sonendo compare to Sintx Technologies?

Sonendo (NYSE:SONX) and Sintx Technologies (NASDAQ:SINT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Sintx Technologies has lower revenue, but higher earnings than Sonendo. Sintx Technologies is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.14	-$60.92M	-$71.12	N/A
Sintx Technologies	$1.02M	8.77	-$10.36M	-$4.91	N/A

In the previous week, Sintx Technologies had 4 more articles in the media than Sonendo. MarketBeat recorded 4 mentions for Sintx Technologies and 0 mentions for Sonendo. Sintx Technologies' average media sentiment score of 0.77 beat Sonendo's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonendo	Neutral
Sintx Technologies	Positive

28.7% of Sonendo shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 7.9% of Sonendo shares are held by insiders. Comparatively, 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sonendo has a net margin of -92.74% compared to Sintx Technologies' net margin of -848.20%. Sonendo's return on equity of -184.01% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
Sintx Technologies	-848.20%	-354.44%	-115.37%

Sintx Technologies has a consensus price target of $9.50, indicating a potential upside of 358.94%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sintx Technologies is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Sintx Technologies beats Sonendo on 8 of the 14 factors compared between the two stocks.

How does Sonendo compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Sonendo (NYSE:SONX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

NeuroOne Medical Technologies presently has a consensus price target of $7.33, indicating a potential upside of 566.67%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NeuroOne Medical Technologies has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Sonendo has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market.

NeuroOne Medical Technologies has a net margin of -71.50% compared to Sonendo's net margin of -92.74%. NeuroOne Medical Technologies' return on equity of -128.12% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%
Sonendo	-92.74%	-184.01%	-68.60%

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 28.7% of Sonendo shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Comparatively, 7.9% of Sonendo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, NeuroOne Medical Technologies had 8 more articles in the media than Sonendo. MarketBeat recorded 8 mentions for NeuroOne Medical Technologies and 0 mentions for Sonendo. NeuroOne Medical Technologies' average media sentiment score of 0.44 beat Sonendo's score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroOne Medical Technologies	Neutral
Sonendo	Neutral

NeuroOne Medical Technologies has higher earnings, but lower revenue than Sonendo. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	0.83	-$3.61M	-$0.95	N/A
Sonendo	$44.40M	0.14	-$60.92M	-$71.12	N/A

Summary

NeuroOne Medical Technologies beats Sonendo on 11 of the 16 factors compared between the two stocks.

Get Sonendo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SONX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SONX vs. The Competition

Export

Metric	Sonendo	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$6.11M	$5.55B	$7.26B	$22.96B
Dividend Yield	N/A	1.75%	2.52%	3.72%
P/E Ratio	-0.02	25.60	275.54	28.29
Price / Sales	0.14	67.27	557.67	20.85
Price / Cash	N/A	32.25	77.16	37.05
Price / Book	0.01	5.82	10.81	4.68
Net Income	-$60.92M	$146.14M	$3.49B	$1.07B
7 Day Performance	N/A	-1.38%	-3.00%	-0.49%
1 Month Performance	-1.54%	-4.06%	-7.48%	-4.13%
1 Year Performance	212.20%	0.95%	3.18%	5.68%

Sonendo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SONX Sonendo	N/A	$1.28 flat	N/A	N/A	$6.11M	$44.40M	N/A	250
CTSO Cytosorbents	2.5198 of 5 stars	$4.31 +2.8%	$107.50 +2,396.5%	-81.4%	$13.72M	$37.06M	N/A	129
TMDIF Titan Medical	N/A	$0.10 -3.2%	N/A	-80.8%	$11.80M	$17.63M	N/A	50	Gap Up
IRIX IRIDEX	2.9079 of 5 stars	$0.64 +0.9%	$3.00 +370.2%	-18.8%	$11.23M	$52.67M	N/A	108	Gap Up
SINT Sintx Technologies	2.6102 of 5 stars	$2.18 +2.3%	$9.50 +336.0%	-48.9%	$9.52M	$1.02M	N/A	32

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SONX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonendo (SONX) Competitors

SONX vs. CTSO, TMDIF, IRIX, SINT, and NMTC

How does Sonendo compare to Cytosorbents?

Summary

How does Sonendo compare to Titan Medical?

Summary

How does Sonendo compare to IRIDEX?

Summary

How does Sonendo compare to Sintx Technologies?

Summary

How does Sonendo compare to NeuroOne Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SONX vs. The Competition

Sonendo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sonendo (SONX) Competitors

SONX vs. CTSO, TMDIF, IRIX, SINT, and NMTC

How does Sonendo compare to Cytosorbents?

Does the media favor SONX or CTSO?

Which has more volatility and risk, SONX or CTSO?

Do insiders and institutionals have more ownership in SONX or CTSO?

Do analysts recommend SONX or CTSO?

Is SONX or CTSO more profitable?

Which has preferable earnings and valuation, SONX or CTSO?

Summary

How does Sonendo compare to Titan Medical?

Do institutionals & insiders hold more shares of TMDIF or SONX?

Does the media prefer TMDIF or SONX?

Which has stronger valuation and earnings, TMDIF or SONX?

Is TMDIF or SONX more profitable?

Which has more volatility & risk, TMDIF or SONX?

Summary

How does Sonendo compare to IRIDEX?

Do analysts recommend IRIX or SONX?

Do insiders and institutionals believe in IRIX or SONX?

Does the media refer more to IRIX or SONX?

Which has stronger earnings & valuation, IRIX or SONX?

Which has more risk & volatility, IRIX or SONX?

Is IRIX or SONX more profitable?

Summary

How does Sonendo compare to Sintx Technologies?

Which has stronger valuation and earnings, SONX or SINT?

Does the media refer more to SONX or SINT?

Do institutionals and insiders have more ownership in SONX or SINT?

Is SONX or SINT more profitable?

Do analysts recommend SONX or SINT?

Summary

How does Sonendo compare to NeuroOne Medical Technologies?

Do analysts rate NMTC or SONX?

Which has more risk and volatility, NMTC or SONX?

Is NMTC or SONX more profitable?

Do institutionals & insiders believe in NMTC or SONX?

Does the media favor NMTC or SONX?

Which has stronger valuation & earnings, NMTC or SONX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SONX vs. The Competition

Sonendo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools